Yeast Bloodstream Infections in the COVID-19 Patient: A Multicenter Italian Study (FiCoV Study)
暂无分享,去创建一个
M. Cogliati | L. Trovato | A. Tortorano | C. Farina | L. Romanò | E. Blasi | A. Prigitano | C. Cavanna | A. Grancini | M. Esposto | P. Innocenti | G. Lo Cascio | M. Cornetta | L. Nicola | M. Calabrò | On Behalf Of The FiCoV Study Group
[1] S. Jagpal,et al. Risk Factors and Clinical Outcomes of Candidemia Associated With Severe COVID-19 , 2022, Critical care explorations.
[2] N. Singla,et al. COVID-19 and Plethora of Fungal Infections , 2022, Current Fungal Infection Reports.
[3] P. Escribano,et al. Incidence of Candidemia Is Higher in COVID-19 versus Non-COVID-19 Patients, but Not Driven by Intrahospital Transmission , 2022, Journal of fungi.
[4] R. Guner,et al. Incidence and risk factors for COVID‐19 associated candidemia (CAC) in ICU patients , 2022, Mycoses.
[5] A. Tortorano,et al. Candidemia: Evolution of Drug Resistance and Novel Therapeutic Approaches , 2021, Infection and drug resistance.
[6] A. Giacomelli,et al. Invasive Fungal Infections Complicating COVID-19: A Narrative Review , 2021, Journal of fungi.
[7] A. Omrani,et al. Clinical Characteristics and Risk Factors for COVID-19-associated Candidemia. , 2021, Medical mycology.
[8] F. Barchiesi,et al. Bloodstream infections in the COVID-19 era: results from an Italian multi-centre study , 2021, International Journal of Infectious Diseases.
[9] T. McCarty. Candidemia and Severe COVID-19 – Which Risk Factors are Modifiable? , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] W. Schaffner,et al. The landscape of candidemia during the COVID-19 pandemic. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] R. Guner,et al. Characteristics of candidemia in COVID‐19 patients; increased incidence, earlier occurrence and higher mortality rates compared to non‐COVID‐19 patients , 2021, Mycoses.
[12] Jordan J. Clark,et al. Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study , 2021, The Lancet. Microbe.
[13] R. Piarroux,et al. Hospital Outbreak of Fluconazole-Resistant Candida parapsilosis: Arguments for Clonal Transmission and Long-Term Persistence , 2021, Antimicrobial Agents and Chemotherapy.
[14] M. Nucci,et al. Increased incidence of candidemia in a tertiary care hospital with the COVID‐19 pandemic , 2020, Mycoses.
[15] A. Lazzarin,et al. Candidemia in COVID-19 patients: incidence and characteristics in a prospective cohort compared to historical non-COVID-19 controls , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] N. Petrosillo,et al. Incidence of bacterial and fungal bloodstream infections in COVID-19 patients in intensive care: An alarming “collateral effect” , 2020, Journal of Global Antimicrobial Resistance.
[17] A. Lazzarin,et al. Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors , 2020, Clinical Microbiology and Infection.
[18] Malik Peiris,et al. Virology, transmission, and pathogenesis of SARS-CoV-2 , 2020, BMJ.
[19] S. Pierson,et al. Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review , 2020, Infectious Diseases and Therapy.
[20] D. McGonagle,et al. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease , 2020, Autoimmunity Reviews.
[21] Bo Diao,et al. Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19) , 2020, Frontiers in Immunology.
[22] C. Viscoli,et al. Changing epidemiology of candidaemia: Increase in fluconazole‐resistant Candida parapsilosis , 2020, Mycoses.
[23] M. Cogliati,et al. Evolution of fungemia in an Italian region. , 2019, Journal de mycologie medicale.
[24] J. Bohlius,et al. Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis. , 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[25] M. Castanheira,et al. Analysis of Global Antifungal Surveillance Results Reveals Predominance of Erg11 Y132F Alteration among Azole-Resistant Candida parapsilosis and Candida tropicalis and Country-Specific Isolate Dissemination. , 2019, International journal of antimicrobial agents.
[26] C. Deluca,et al. Method-Dependent Epidemiological Cutoff Values for Detection of Triazole Resistance in Candida and Aspergillus Species for the Sensititre YeastOne Colorimetric Broth and Etest Agar Diffusion Methods , 2018, Antimicrobial Agents and Chemotherapy.
[27] A. Chowdhary,et al. Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally , 2017, PLoS pathogens.
[28] G. Lombardi,et al. CAND-LO 2014–15 study: changing epidemiology of candidemia in Lombardy (Italy) , 2016, Infection.
[29] Y. Carmeli,et al. Risk factors for albicans and non-albicans candidemia in the intensive care unit* , 2008, Critical care medicine.
[30] Clinical,et al. Reference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard , 2008 .
[31] A Lepape,et al. European surveillance of ICU-acquired infections (HELICS-ICU): methods and main results. , 2007, The Journal of hospital infection.